TRACON Pharmaceuticals
Market Cap
US$16.2m
Last Updated
2020/01/21 01:02 UTC
Data Sources
Company Financials +
Executive Summary
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD).
Rewards
Risk Analysis
Earnings are forecast to decline by an average of -5.7% per year for the next 3 years
Currently unprofitable and not forecast to become profitable over the next 3 years
+ 3 more risks
Snowflake Analysis
Imperfect balance sheet and overvalued.
Share Price & News
How has TRACON Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: TCON's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
41.4%
TCON
1.2%
US Biotechs
1.2%
US Market
1 Year Return
-61.9%
TCON
12.4%
US Biotechs
24.2%
US Market
Return vs Industry: TCON underperformed the US Biotechs industry which returned 10.9% over the past year.
Return vs Market: TCON underperformed the US Market which returned 24.7% over the past year.
Shareholder returns
| TCON | Industry | Market | |
|---|---|---|---|
| 7 Day | 41.4% | 1.2% | 1.2% |
| 30 Day | 62.3% | 0.2% | 3.5% |
| 90 Day | 34.9% | 17.5% | 11.7% |
| 1 Year | -61.9%-61.9% | 13.4%12.4% | 26.9%24.2% |
| 3 Year | -91.9%-91.9% | 30.1%25.8% | 53.0%43.2% |
| 5 Year | n/a | 2.6%-2.3% | 75.3%56.0% |
Price Volatility Vs. Market
How volatile is TRACON Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
Introducing TRACON Pharmaceuticals (NASDAQ:TCON), The Stock That Tanked 92%6 months ago | Simply Wall St
What Kind Of Shareholder Appears On The TRACON Pharmaceuticals, Inc.'s (NASDAQ:TCON) Shareholder Register?7 months ago | Simply Wall St
Does TRACON Pharmaceuticals, Inc.'s (NASDAQ:TCON) CEO Pay Compare Well With Peers?Valuation
Is TRACON Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
2.94x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TCON's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate TCON's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: TCON is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: TCON is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TCON's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TCON is good value based on its PB Ratio (2.1x) compared to the US Biotechs industry average (3.2x).
Next Steps
Future Growth
How is TRACON Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-5.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TCON is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TCON is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TCON is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TCON's revenue (29.6% per year) is forecast to grow faster than the US market (7.5% per year).
High Growth Revenue: TCON's revenue (19.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TCON's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has TRACON Pharmaceuticals performed over the past 5 years?
-17.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TCON is currently unprofitable.
Growing Profit Margin: TCON is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TCON is unprofitable, and losses have increased over the past 5 years at a rate of -17.3% per year.
Accelerating Growth: Unable to compare TCON's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TCON is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (103.3%).
Return on Equity
High ROE: TCON has a negative Return on Equity (-656.6%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is TRACON Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: TCON's short term assets ($20.3M) exceed its short term liabilities ($12.8M).
Long Term Liabilities: TCON's short term assets ($20.3M) exceed its long term liabilities ($4.3M).
Debt to Equity History and Analysis
Debt Level: TCON's debt to equity ratio (148%) is considered high.
Reducing Debt: TCON's debt to equity ratio has increased from 46.5% to 148% over the past 5 years.
Balance Sheet
Inventory Level: TCON has a low level of unsold assets or inventory.
Debt Coverage by Assets: TCON's debt is covered by short term assets (assets are 3.4x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TCON has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TCON has less than a year of cash runway if free cash flow continues to reduce at historical rates of -4.6% each year
Next Steps
Dividend
What is TRACON Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate TCON's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate TCON's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TCON's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TCON's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of TCON's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of TRACON Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
1.7yrs
Average management tenure
CEO
Charles Theuer (55yo)
13.6yrs
Tenure
US$1,111,616
Compensation
Dr. Charles P. Theuer, M.D., Ph.D., has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since June 2006 and has been its Director of Tracon Pharmaceuticals, Inc. since June 2Â ...
CEO Compensation Analysis
Compensation vs Market: Charles's total compensation ($USD1.11M) is above average for companies of similar size in the US market ($USD519.76K).
Compensation vs Earnings: Charles's compensation has been consistent with company performance over the past year.
Management Age and Tenure
1.7yrs
Average Tenure
48.5yo
Average Age
Experienced Management: TCON's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Age and Tenure
5.3yrs
Average Tenure
61yo
Average Age
Experienced Board: TCON's board of directors are considered experienced (5.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Company |
| Shares | 207,138 |
| Max Price | US$3.05 |
| Entity | Individual |
| Role | Chief Executive Officer CEO, President & Director |
| Shares | 5,000 |
| Max Price | US$4.50 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.3%.
Management Team
Mark Wiggins (63yo)
Chief Business Officer
- Tenure: 1.7yrs
- Compensation: US$979.41k
Charles Theuer (55yo)
CEO, President & Director
- Tenure: 13.6yrs
- Compensation: US$1.11m
Bonne Adams (42yo)
Executive Vice President of Clinical Operations
- Tenure: 5.5yrs
Suzy Benedict
Senior Vice President of Regulatory Affairs
- Tenure: 1yrs
Scott Brown (39yo)
Chief Accounting Officer & Head of Finance
- Tenure: 1yrs
Board Members
Paul Walker (44yo)
Independent Director
- Tenure: 5.3yrs
- Compensation: US$77.38k
Steve Worland (61yo)
Independent Director
- Tenure: 4.9yrs
- Compensation: US$73.63k
Bill LaRue (68yo)
Independent Director
- Tenure: 5.5yrs
- Compensation: US$82.38k
Martin Mattingly (62yo)
Independent Director
- Tenure: 5.1yrs
- Compensation: US$76.13k
Charles Theuer (55yo)
CEO, President & Director
- Tenure: 13.6yrs
- Compensation: US$1.11m
Bill Kaelin (61yo)
Member of the Scientific Advisory Board
James Twiford (66yo)
Independent Director
- Tenure: 11.3yrs
- Compensation: US$67.38k
Stan Gerson
Member of the Scientific Advisory Board
Jeff Hager (55yo)
Member of the Scientific Advisory Board
- Tenure: 3.1yrs
Company Information
TRACON Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: TRACON Pharmaceuticals, Inc.
- Ticker: TCON
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.236m
- Shares outstanding: 4.10m
- Website: https://www.traconpharma.com
Number of Employees
Location
- TRACON Pharmaceuticals, Inc.
- 4350 La Jolla Village Drive
- Suite 800
- San Diego
- California
- 92122
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| TCON | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Jan 2015 |
| T051 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jan 2015 |
Biography
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD. The company also develops TRC102, a small molecule that is in Phase II clinical trial for mesothelioma, Phase I clinical trial for solid tumors and lung cancer, and Phase I/II clinical trial for solid tumors and lymphomas; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trial for the treatment prostate cancer. In addition, it is developing TJ004309, a novel humanized antibody against CD73 that is in Phase I clinical trial to treat patients with solid tumors through a strategic collaboration and clinical trial agreement with I-Mab Biopharma. The company has license agreements with Ambrx, Inc.; Santen Pharmaceutical Co. Ltd.; Roswell Park Cancer Institute and Health Research Inc.; Case Western Cancer Center; and Lonza Sales AG, as well as a cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/01/21 01:02 |
| End of Day Share Price | 2020/01/17 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.